Camrelizumab in advanced or metastatic solid tumour patients with DNA mismatch repair deficient or microsatellite instability high: an open-label prospective pivotal trial.

Jingde ChenMing QuanZhiqin ChenTianmei ZengYandong LiYing ZhouYanan HaiYong Gao

Published in: Journal of cancer research and clinical oncology (2020)

Camrelizumab provided durable objective response and disease control in pre-treated patients with dMMR/MSI-H advanced or metastatic solid tumour, being a promising treatment option for these patients.

Keyphrases

end stage renal disease
squamous cell carcinoma
small cell lung cancer
newly diagnosed
ejection fraction
chronic kidney disease
clinical trial
prognostic factors
study protocol
peritoneal dialysis
cell free
single molecule
smoking cessation